Teleconference: Study of Tamoxifen and Raloxifene (STAR) P-2

Breast Cancer Prevention: Raloxifene as Effective as Tamoxifen with Fewer Side Effects

Raloxifene improved its effectiveness against noninvasive breast cancer, caused significantly less endometrial cancer and was significantly less toxic than tamoxifen. Full results of the Study of Tamoxifen and Raloxifene (STAR) P-2 trial in breast cancer prevention are discussed in this press conference by a panel of experts.

Download the teleconference (29.3 MB file; 42:41 minutes duration. Requires QuickTime).